

Lauren J Rogak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5465840/publications.pdf>

Version: 2024-02-01

20
papers

2,415
citations

471509

17
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

3534
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014, 106, dju244-dju244. | 6.3 | 689 |
| 2 | Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015, 1, 1051. | 7.1 | 581 |
| 3 | The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 3669-3676. | 2.2 | 249 |
| 4 | Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2413. | 7.4 | 108 |
| 5 | Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043. | 7.1 | 98 |
| 6 | Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 947-957. | 2.1 | 97 |
| 7 | Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Health and Quality of Life Outcomes</i> , 2016, 14, 24. | 2.4 | 91 |
| 8 | Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 409-418. | 0.8 | 87 |
| 9 | Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. <i>Clinical Therapeutics</i> , 2016, 38, 821-830. | 2.5 | 77 |
| 10 | Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. <i>Clinical Trials</i> , 2017, 14, 255-263. | 1.6 | 58 |
| 11 | Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 276-285. | 4.4 | 46 |
| 12 | Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. <i>Journal of Clinical Oncology</i> , 2018, 36, 3120-3125. | 1.6 | 45 |
| 13 | Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. <i>Clinical Trials</i> , 2016, 13, 331-337. | 1.6 | 40 |
| 14 | Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. <i>JAMA Oncology</i> , 2020, 6, e193332. | 7.1 | 39 |
| 15 | Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 735-743. | 2.5 | 36 |
| 16 | Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Supportive Care in Cancer</i> , 2016, 24, 2843-2851. | 2.2 | 28 |
| 17 | Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. <i>JMIR Human Factors</i> , 2018, 5, e10070. | 2.0 | 20 |
| 18 | The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. <i>Journal of Psychosocial Oncology</i> , 2021, 39, 285-293. | 1.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 890-899. | 1.1 | 4 |
| 20 | Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 56. | 1.9 | 4 |